Navigation Links
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
Date:2/13/2008

270

TOTAL REVENUE $4,500 $4,700

**GROSS MARGIN approx. 77%

**SG&A approx. 27%

**R&D approx. 17%

Net Interest / Other approx. 60

TAX RATE - GAAP approx. 30%

*TAX RATE - NON-GAAP approx. 31%

GENZ GAAP EPS approx. $2.75

AMORTIZATION approx. $0.55

FAS123 EXPENSE approx. $0.60

CONTINGENT CONVERTIBLE DEBT approx. $0.10

**GENZ NON-GAAP EPS $4.00

***WTD AVERAGE SHARES O/S approx. 274

CAPITAL EXPENDITURES approx. $500

This financial guidance, which is provided as part of a press release dated February 13, 2008, is subject to all of the qualifications and limitations described therein. Actual results may differ from these forward- looking statements due to the numerous factors described in the press release.

*Non-GAAP tax rate excludes the impact of amortization, one-time events,

FIN 46, FAS123 expense and EITF 04-08.

**Non-GAAP excludes the impact of amortization, one-time events, FIN 46,

FAS123 expense and EITF 04-08.

***WTD Average Shares Outstanding excludes the impact of EITF 04-08.


'/>"/>
SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
2. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
3. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Delaware Court Approves Bioenvision, Genzyme Joint Petition
6. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
7. Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities
8. March of Dimes Delivers a New Look
9. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
11. Gleevec, the targeted cancer pill, delivers more good news to patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Rockville, MD (PRWEB) July 31, 2014 ... in San Francisco, announced that they will upgrade all ... including MoSo, MyClub, and MoSo Pay. Motionsoft is a ... cloud-based solutions that automate member management and payments services ... cloud-based member relationship management suite, which FITNESS SF bundled ...
(Date:7/31/2014)... July 31, 2014 Web Programming Services, ... 9001:2008 certified internet marketing firm, has recently launched a ... make this service affordable for everyone, the company has ... service. , Web Programming Services has tailored the ... of brochure designing and likely expectations of the clients ...
(Date:7/31/2014)... News) -- Recovery time after surgery may be reduced ... according to a new study. The study,s Irish ... inflammatory response, reducing the amount of time surgical patients, ... particularly true among people who tend to have healing ... widely prescribed medications in the world. While they are ...
(Date:7/31/2014)... July 31, 2014 Ethane Web ... has introduced a new service named ‘Java Development’. ... Web Technologies has designed the service after doing ... and Java Development service being provided by other ... a confidence to promise outstanding Java Development service. ...
(Date:7/31/2014)... the unusual property of destroying itself after a few hours ... is no stable protein. The protein, called PAI-1, affects many ... get a blood clot, it is due to the fact ... and therefore PAI-1 is extremely important for the human ... blood clot or other blood diseases in which coagulation plays ...
Breaking Medicine News(10 mins):Health News:FITNESS SF Upgrades Motionsoft Software to Include Entire Product Lineup: MoSo + MoSo Pay + MyClub 2Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:Ethane Web Technologies Announces Java Development Service at Pocket Friendly Cost 2Health News:Breakthrough in understanding of important blood protein 2Health News:Breakthrough in understanding of important blood protein 3
... Research conducted at the University of California, San Diego ... the structure and function of one of the key ... an enzyme which plays an essential role in memory ... Utilizing a process called x-ray crystallography, the scientists solved ...
... ARBOR, Mich. - A cancer diagnosis affects more than just ... of Michigan Comprehensive Cancer Center finds spouses report similar physical ... The study found that what really impacted emotional distress - ... patient was newly diagnosed, facing a recurrence or living with ...
... the results of a recent National Academy of Sciences ... should be restored to the U.S. Department of Energy, ... and nuclear medicine professionals. , Funded by the Department ... 13-month, $700,000 report was prompted by a $23 million ...
... the top 25 most influential in the field of ... PhD, CAE, at the number 10 ranking. RT Image ... a roster of radiologys most powerful people, institutions and ... was singled out for his consistent guidance in the ...
... 21 Business Roundtable and,the American Red ... Partnership for Disaster Response. The Partnership is ... contribute its vast,resources -- beyond financial contributions ... following major national disasters. This,announcement is timed ...
... Eli Lilly and Company,(NYSE: LLY ) today ... in,November 2007, as a Distinguished Lilly Scholar focusing ... to recruit someone with Dr. Marangell,s stature and,depth ... M.D., vice president,U.S. medical division. "Lauren brings a ...
Cached Medicine News:Health News:UCSD study reveals the regulatory mechanism of key enzyme 2Health News:Cancer patients, spouses report similar emotional distress, U-M study finds 2Health News:SNM applauds NAS study showing need to restore federal nuclear medicine research funding 2Health News:SNM applauds NAS study showing need to restore federal nuclear medicine research funding 3Health News:AIUM CEO named among 'most influential' in radiology 2Health News:Video and Photo: Leading CEOs Launch Alliance With American Red Cross to Strengthen Nation's Preparedness for Disasters 2Health News:Video and Photo: Leading CEOs Launch Alliance With American Red Cross to Strengthen Nation's Preparedness for Disasters 3Health News:Video and Photo: Leading CEOs Launch Alliance With American Red Cross to Strengthen Nation's Preparedness for Disasters 4Health News:Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar 2
(Date:7/31/2014)... July 31, 2014 Auxilium Pharmaceuticals, ... specialty biopharmaceutical company, today announced that the Company ... from its partner Asahi Kasei Pharma Corporation (Asahi ... successful submission of a regulatory application to the ... XIAFLEX ® (collagenase clostridium histolyticum) for the ...
(Date:7/30/2014)...  There is still time to share your ... Annual Institute for Supply Management ® – ... Management is open for submissions.  The annual competition ... of supply management by recognizing supply management organizations ... practices.  Entries are due August 22, 2014. ...
(Date:7/30/2014)... CryoLife, Inc. (NYSE: CRY), a leading medical ... vascular surgery, announced today that its Board of Directors ... quarter 2014 of $0.03 per share of common stock ... will be paid on September 19, 2014 to all ... The ex-dividend date for the quarterly dividend is September ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 5Institute for Supply Management, Michigan State University to recognize companies with excellent supply management practices 2CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 2CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 3
... II data show RAD001 significantly increased efficacy of, letrozole tablets in women with newly diagnosed hormone-positive ... cancer, ... ... breast cancer by ...
... Presented at ASCO Annual Meeting -, ... 1 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: ... today announced safety and efficacy results,from a ... picoplatin and,liposomal doxorubicin in patients with advanced ...
Cached Medicine Technology:Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 2Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 3Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 4Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 5Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 6Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 7Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 8Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 9Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer 2Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer 3Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer 4Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer 5
... Shaker provides the exact agitation needed ... very slow to fast speed and ... a gentle wave motion that lifts ... membranes to achieve faster, more uniform ...
Conversion Kits For Modular Incubator Chamber...
Conversion Kits For Modular Incubator Chamber...
Inquire...
Medicine Products: